Genus plc

LSE:GNS Stock Report

Market Cap: UK£1.2b

Genus Valuation

Is GNS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GNS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
UK£23.02
Fair Value
19.0% undervalued intrinsic discount
8
Number of Analysts

Below Fair Value: GNS (£18.64) is trading below our estimate of fair value (£23.02)

Significantly Below Fair Value: GNS is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GNS?

Key metric: As GNS is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GNS. This is calculated by dividing GNS's market cap by their current revenue.
What is GNS's PS Ratio?
PS Ratio1.8x
SalesUK£668.80m
Market CapUK£1.17b

Price to Sales Ratio vs Peers

How does GNS's PS Ratio compare to its peers?

The above table shows the PS ratio for GNS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.6x
OXB Oxford Biomedica
4.6x21.2%UK£448.1m
BVXP Bioventix
12.3xn/aUK£167.0m
AVCT Avacta Group
7.7x0.4%UK£173.8m
TRX Tissue Regenix Group
1.6x15.1%UK£42.0m
GNS Genus
1.8x3.5%UK£1.2b

Price-To-Sales vs Peers: GNS is good value based on its Price-To-Sales Ratio (1.8x) compared to the peer average (6.6x).

Price to Sales Ratio vs Industry

How does GNS's PS Ratio compare vs other companies in the GB Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.n/a16.5%
GNS Genus
 1.8x3.5%US$1.52b
OXB Oxford Biomedica
4.6x21.2%US$557.10m
TRX Tissue Regenix Group
1.6x15.1%US$52.25m
No. of Companies7PS020406080100+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.n/a38.7%
GNS Genus
 1.8x37.2%US$1.52b
No more companies

Price-To-Sales vs Industry: GNS is good value based on its Price-To-Sales Ratio (1.8x) compared to the European Biotechs industry average (8.4x).

Price to Sales Ratio vs Fair Ratio

What is GNS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GNS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.8x
Fair PS Ratio2.2x

Price-To-Sales vs Fair Ratio: GNS is good value based on its Price-To-Sales Ratio (1.8x) compared to the estimated Fair Price-To-Sales Ratio (2.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GNS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£18.64
UK£24.64
+32.2%
14.8%UK£31.00UK£18.50n/a8
Jan ’26UK£15.50
UK£24.23
+56.3%
15.6%UK£31.00UK£18.50n/a7
Dec ’25UK£17.16
UK£26.33
+53.4%
12.5%UK£31.00UK£22.50n/a6
Nov ’25UK£21.00
UK£26.33
+25.4%
12.5%UK£31.00UK£22.50n/a6
Oct ’25UK£20.10
UK£26.16
+30.1%
13.4%UK£31.00UK£21.50n/a6
Sep ’25UK£17.84
UK£26.66
+49.4%
12.1%UK£31.00UK£21.50n/a6
Aug ’25UK£18.24
UK£26.50
+45.3%
12.7%UK£31.00UK£21.50n/a6
Jul ’25UK£16.56
UK£27.78
+67.8%
15.9%UK£35.00UK£23.00n/a6
Jun ’25UK£18.02
UK£27.78
+54.2%
15.9%UK£35.00UK£23.00n/a6
May ’25UK£17.36
UK£27.78
+60.0%
15.9%UK£35.00UK£23.00n/a6
Apr ’25UK£17.65
UK£29.62
+67.8%
14.7%UK£35.00UK£23.09n/a6
Mar ’25UK£17.40
UK£29.62
+70.2%
14.7%UK£35.00UK£23.09n/a6
Feb ’25UK£22.24
UK£33.09
+48.8%
20.9%UK£45.00UK£23.17n/a6
Jan ’25UK£21.70
UK£33.09
+52.5%
20.9%UK£45.00UK£23.17UK£15.506
Dec ’24UK£19.09
UK£33.09
+73.3%
20.9%UK£45.00UK£23.17UK£17.166
Nov ’24UK£21.82
UK£34.10
+56.3%
16.7%UK£45.00UK£27.80UK£21.006
Oct ’24UK£20.96
UK£34.10
+62.7%
18.1%UK£45.00UK£25.80UK£20.106
Sep ’24UK£23.00
UK£35.59
+54.7%
14.9%UK£45.00UK£30.42UK£17.846
Aug ’24UK£24.40
UK£38.82
+59.1%
17.9%UK£50.00UK£30.42UK£18.246
Jul ’24UK£21.66
UK£38.82
+79.2%
17.9%UK£50.00UK£30.42UK£16.566
Jun ’24UK£25.18
UK£38.82
+54.2%
17.9%UK£50.00UK£30.42UK£18.026
May ’24UK£26.88
UK£42.36
+57.6%
21.2%UK£60.00UK£32.00UK£17.366
Apr ’24UK£28.74
UK£42.36
+47.4%
21.2%UK£60.00UK£32.00UK£17.656
Mar ’24UK£29.98
UK£43.80
+46.1%
20.9%UK£60.00UK£32.00UK£17.405
Feb ’24UK£28.50
UK£42.95
+50.7%
17.3%UK£57.00UK£32.00UK£22.246
Jan ’24UK£29.84
UK£42.95
+43.9%
17.3%UK£57.00UK£32.00UK£21.706
Analyst Price Target
Consensus Narrative from 8 Analysts
UK£24.64
Fair Value
24.4% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/29 19:59
End of Day Share Price 2025/01/29 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genus plc is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert ChantryBerenberg
Francesco GregoriCharles Stanley Securities
Benjamin MooreGoldman Sachs